Immunization News and Research

RSS

Nucleocapsid-based vaccines may prevent SARS-CoV-2 dissemination to distal organs

A team of scientists recently investigated and compared the efficacy of spike-based and nucleocapsid-based COVID-19 vaccines in mice infected with SARS-CoV-2. Their findings reveal that nucleocapsid-based vaccines are effective in preventing SARS-CoV-2 infection in distal organs, such as the brain.

27 Apr 2021

World Immunization Week: Vaccination in 2021

News-Medical talks to experts in different areas of the medical sector on why immunization week is so prevalent in 2021.

27 Apr 2021

Nanobodies neutralize SARS-CoV-2 in pre-clinical model

A team of Australian researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI), the Doherty Institute, and the Kirby Institute have identified neutralizing nanobody cocktails that block the SARS-CoV-2 virus from entering cells in pre-clinical models.

27 Apr 2021

Prior SARS-CoV-2 infection and Pfizer-BioNTech’s COVID-19 vaccine provide similar immunity

Researchers in Israel have conducted a study showing that the immunity provided against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease (COVID-19) – is similar following natural infection or immunization with the Pfizer-BioNTech BNT162b2 vaccine.

26 Apr 2021

Study to evaluate how people with immune system deficiencies respond to COVID-19 vaccination

A study assessing how people with immune system deficiencies or dysregulations respond to COVID-19 vaccination has begun enrolling participants at the National Institutes of Health Clinical Center in Bethesda, Maryland.

26 Apr 2021

A detailed look at two cases of symptomatic COVID in vaccinated individuals

In a recent brief report published in the prestigious New England Journal of Medicine, researchers from the Rockefeller University in New York described a case of two fully vaccinated individuals in whom they found subsequent breakthrough infections with variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), carrying a number of substitutions of interest.

25 Apr 2021

FDA, CDC lift recommended pause on the use of Janssen COVID-19 vaccine in the U.S.

Following a thorough safety review, including two meetings of the CDC's Advisory Committee on Immunization Practices, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention have determined that the recommended pause regarding the use of the Johnson & Johnson (Janssen) COVID-19 Vaccine in the U.S. should be lifted and use of the vaccine should resume.

23 Apr 2021

Disruptions to essential health services due to COVID-19 pandemic persist in 90% of countries

The second round of a World Health Organization "pulse survey" reveals that over one year into the COVID-19 pandemic, substantial disruptions persist, with about 90% of countries still reporting one or more disruptions to essential health services, marking no substantial global change since the first survey conducted in the summer of 2020.

23 Apr 2021

World Malaria Day 2021: An interview with Sir Brian Greenwood

News-Medical interviews Sir Brian Greenwood about raising awareness for malaria during the COVID-19 pandemic and achieving elimination of the disease.

23 Apr 2021

DNA vaccine candidate induces potent immunity, offers protective efficacy in non-human primate models

A synthetic DNA vaccine candidate for Middle East respiratory syndrome coronavirus (MERS-CoV) developed at The Wistar Institute induced potent immune responses and afforded protective efficacy in non-human primate (NHP) models when given intradermally in abbreviated, low-dose immunization regimen.

23 Apr 2021

Celastrol shows potential anti-SARS-CoV-2 activity

A new study published on the bioRxiv* preprint server focuses on the in-silico predictions to repurpose existing drug compounds, that may have the ability to reverse the SARS-CoV-2 gene expression induced in host cells.

23 Apr 2021

Preclinical study from NIH/Moderna: Correlates of SARS-CoV-2 immunity in non-human primates

Researchers in the United States have shown that the antibody response induced by the Moderna mRNA-1273 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a correlate of immune protection against coronavirus disease 2019 (COVID-19) in non-human primates.

22 Apr 2021

SARS-CoV-2 vaccine with single-cycle adenovirus vector

Researchers in the United States have developed adenovirus vectors that may be more effective at generating immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than those used in the vaccines that are currently being rolled out to help combat the coronavirus disease 2019 (COVID-19) pandemic.

21 Apr 2021

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

21 Apr 2021

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

A new study led by Hans-Martin Jäck of the Friedrich-Alexander University Erlangen-Nuremberg in Germany engineered clusters of neutralizing monoclonal antibodies using a transgenic mouse model. A unique characteristic for the antibodies was the different ways it bound to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the overall reduction in the viral spread for human ACE2.

21 Apr 2021

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

To monitor antibody level duration of vaccine-induced immune responses, a team of researchers in the U.S. – at Diacarta, University of California and VA Healthcare System, and the Franciscan University of Steubenville – evaluated the feasibility of using a single drop of fingerstick blood collected with flocked swabs for quantitative antibody response evaluation after COVID-19 vaccination.

20 Apr 2021

Scientists receive NIH grant to develop an adjuvant vaccine for opioid use disorder

Opioid addicts wage a daily war within over whether or not to use a drug whose side effect can be death. If those same addicts, however, had the choice to take an opioid vaccine once or twice a year, their internal struggle could be over.

20 Apr 2021

Just one mRNA vaccine dose sufficient for people with prior SARS-CoV-2 infection

A small study, previously posted to the medRiv preprint server in early March, was recently published in the journal Science Immunology. The now peer-reviewed research led by E. John Wherry of the University of Pennsylvania Perelman School of Medicine finds people previously exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produced a more robust immune response after receiving the first — but not the second mRNA vaccine.

19 Apr 2021

Researchers develop computational model to predict changes in SARS-CoV-2’s viral fitness

Two researchers from the Université Libre de Bruxelles in Belgium, Fabrizio Pucci and Marianne Rooman, recently built a simplified computational model, called SpikePro, to predict the SARS-CoV-2 fitness from the amino acid sequence and structure of the spike protein. This study focuses on the spike protein’s stability and the binding affinity to the host receptor.

19 Apr 2021

Research says benefits of continuing immunization of front-line workers in BC with AstraZeneca vaccine far outweigh risks

A recent study by researchers at the University of British Columbia (B.C.) shows that the benefits of continuing the COVID-19 vaccine of front-line workers with the AstraZeneca vaccine outweigh the increased risk of prothrombotic thrombocytopenia.

19 Apr 2021

Immunization News and Research

Nucleocapsid-based vaccines may prevent SARS-CoV-2 dissemination to distal organs

World Immunization Week: Vaccination in 2021

Nanobodies neutralize SARS-CoV-2 in pre-clinical model

Prior SARS-CoV-2 infection and Pfizer-BioNTech’s COVID-19 vaccine provide similar immunity

Study to evaluate how people with immune system deficiencies respond to COVID-19 vaccination

A detailed look at two cases of symptomatic COVID in vaccinated individuals

FDA, CDC lift recommended pause on the use of Janssen COVID-19 vaccine in the U.S.

Disruptions to essential health services due to COVID-19 pandemic persist in 90% of countries

World Malaria Day 2021: An interview with Sir Brian Greenwood

DNA vaccine candidate induces potent immunity, offers protective efficacy in non-human primate models

Celastrol shows potential anti-SARS-CoV-2 activity

Preclinical study from NIH/Moderna: Correlates of SARS-CoV-2 immunity in non-human primates

SARS-CoV-2 vaccine with single-cycle adenovirus vector

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

Scientists receive NIH grant to develop an adjuvant vaccine for opioid use disorder

Just one mRNA vaccine dose sufficient for people with prior SARS-CoV-2 infection

Researchers develop computational model to predict changes in SARS-CoV-2’s viral fitness

Research says benefits of continuing immunization of front-line workers in BC with AstraZeneca vaccine far outweigh risks

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News